000284357 001__ 284357
000284357 005__ 20260130145544.0
000284357 0247_ $$2doi$$a10.1007/s00702-025-02923-1
000284357 0247_ $$2pmid$$apmid:40299066
000284357 0247_ $$2ISSN$$a0375-9245
000284357 0247_ $$2ISSN$$a0022-3026
000284357 0247_ $$2ISSN$$a0300-9564
000284357 0247_ $$2ISSN$$a1435-1463
000284357 037__ $$aDZNE-2026-00125
000284357 041__ $$aEnglish
000284357 082__ $$a610
000284357 1001_ $$aBuhmann, C.$$b0
000284357 245__ $$aParkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?
000284357 260__ $$aWien [u.a.]$$bSpringer$$c2026
000284357 3367_ $$2DRIVER$$aarticle
000284357 3367_ $$2DataCite$$aOutput Types/Journal article
000284357 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769781200_7560$$xReview Article
000284357 3367_ $$2BibTeX$$aARTICLE
000284357 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284357 3367_ $$00$$2EndNote$$aJournal Article
000284357 520__ $$aThe demographic development and the advance of intensified yet time and personnel-intensive therapeutic options constitute increasing challenges for the care of people with advanced Parkinson's disease (PD). Often, the multitude of motor and non-motor symptoms cannot be adequately addressed in an ambulatory setting The concept of a Parkinson's day clinic has been put forward to meet the requirements for these patients who not necessarily require the full medical support of an inpatient treatment and was included into the Parkinson's guidelines of the German Neurological Society as a novel and promising medical care model. While the guidelines put forward some recommendations as to which patients are most likely to benefit from treatment in a Parkinson's day clinic, it has not yet been decided which infrastructural, operational, personnel and qualitative requirements such a setting should provide. Here we provide recommendations on the basis of an expert consensus as to which patients will particularly benefit from treatment in a Parkinson´s day clinic and which services such a day clinic should address in order to provide successful therapy. Furthermore we suggest a standard operating procedure (SOP) and we give examples of patients who are suitable for treatment in a Parkinson´s day clinic.
000284357 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000284357 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000284357 650_7 $$2Other$$aConcept
000284357 650_7 $$2Other$$aDay-clinic
000284357 650_7 $$2Other$$aDay-hospital
000284357 650_7 $$2Other$$aParkinson
000284357 650_7 $$2Other$$aRequirements
000284357 650_2 $$2MeSH$$aHumans
000284357 650_2 $$2MeSH$$aParkinson Disease: therapy
000284357 650_2 $$2MeSH$$aDay Care, Medical: standards
000284357 650_2 $$2MeSH$$aDay Care, Medical: methods
000284357 650_2 $$2MeSH$$aPatient Selection
000284357 650_2 $$2MeSH$$aPractice Guidelines as Topic: standards
000284357 7001_ $$aKalbe, E.$$b1
000284357 7001_ $$aClaus, I.$$b2
000284357 7001_ $$aHilker-Roggendorf, R.$$b3
000284357 7001_ $$0P:(DE-HGF)0$$aMüller, T.$$b4
000284357 7001_ $$aIp, C. W.$$b5
000284357 7001_ $$0P:(DE-2719)2000056$$aWüllner, U.$$b6$$eLast author$$udzne
000284357 7001_ $$aKrüger, R.$$b7
000284357 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-025-02923-1$$gVol. 133, no. 2, p. 325 - 333$$n2$$p325 - 333$$tJournal of neural transmission$$v133$$x0375-9245$$y2026
000284357 8564_ $$uhttps://pub.dzne.de/record/284357/files/DZNE-2026-00125_Restricted.pdf
000284357 8564_ $$uhttps://pub.dzne.de/record/284357/files/DZNE-2026-00125_Restricted.pdf?subformat=pdfa$$xpdfa
000284357 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000056$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000284357 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000284357 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284357 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284357 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000284357 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000284357 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x0
000284357 980__ $$ajournal
000284357 980__ $$aEDITORS
000284357 980__ $$aVDBINPRINT
000284357 980__ $$aI:(DE-2719)1011302
000284357 980__ $$aUNRESTRICTED